X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (122) 122
oncology (113) 113
humans (112) 112
melanoma (66) 66
female (60) 60
male (54) 54
middle aged (53) 53
aged (45) 45
cancer (43) 43
adult (40) 40
melanoma - drug therapy (40) 40
chemotherapy (37) 37
treatment outcome (33) 33
care and treatment (32) 32
ipilimumab (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
aged, 80 and over (28) 28
immunotherapy (28) 28
antineoplastic agents - therapeutic use (27) 27
hematology, oncology and palliative medicine (26) 26
metastasis (26) 26
survival (26) 26
melanoma - pathology (25) 25
skin neoplasms - drug therapy (25) 25
lung neoplasms - drug therapy (24) 24
skin neoplasms - pathology (24) 24
metastatic melanoma (22) 22
neoplasm staging (22) 22
drug therapy (21) 21
lung neoplasms - pathology (21) 21
survival analysis (21) 21
disease-free survival (20) 20
prognosis (20) 20
research (20) 20
antibodies, monoclonal - therapeutic use (19) 19
clinical trials (19) 19
melanoma - mortality (17) 17
mutation (17) 17
patients (17) 17
analysis (16) 16
kaplan-meier estimate (16) 16
cisplatin (15) 15
lung cancer (15) 15
tumors (15) 15
vemurafenib (15) 15
dermatology (14) 14
etoposide (14) 14
adolescent (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
chemistry (13) 13
compositions based thereon (13) 13
melanoma - secondary (13) 13
metallurgy (13) 13
organic macromolecular compounds (13) 13
their preparation or chemical working-up (13) 13
therapy (13) 13
abridged index medicus (12) 12
after-treatment not covered by subclasses c08b, c08c, c08f,c08g (12) 12
basic electric elements (12) 12
cables (12) 12
compositions of macromolecular compounds (12) 12
conductors (12) 12
electricity (12) 12
etoposide - administration & dosage (12) 12
general processes of compounding (12) 12
insulators (12) 12
lung neoplasms - therapy (12) 12
selection of materials for their conductive, insulating ordielectric properties (12) 12
trial (12) 12
use of inorganic or non-macromolecular organic substances ascompounding ingredients (12) 12
working-up (12) 12
antineoplastic agents - administration & dosage (11) 11
combined modality therapy (11) 11
health aspects (11) 11
respiratory system (11) 11
skin neoplasms - mortality (11) 11
small cell lung carcinoma - drug therapy (11) 11
small cell lung carcinoma - pathology (11) 11
time factors (11) 11
young adult (11) 11
antineoplastic agents - adverse effects (10) 10
carboplatin (10) 10
carboplatin - administration & dosage (10) 10
combination (10) 10
dacarbazine (10) 10
drug administration schedule (10) 10
expression (10) 10
lung cancer, small cell (10) 10
melanoma - genetics (10) 10
melanoma - therapy (10) 10
nivolumab (10) 10
oncology, experimental (10) 10
pembrolizumab (10) 10
proto-oncogene proteins b-raf - antagonists & inhibitors (10) 10
pulmonary/respiratory (10) 10
quality of life (10) 10
skin cancer (10) 10
toxicity (10) 10
antineoplastic agents - pharmacology (9) 9
cell biology (9) 9
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (230) 230
French (2) 2
Danish (1) 1
Finnish (1) 1
German (1) 1
Norwegian (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2007, Dana-Farber Cancer Institute handbook series, ISBN 9780723434375, vii, 158
Book
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 26, pp. 2507 - 2516
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 620 - 630
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 616 - 622
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 4, pp. 375 - 384
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1116 - 1125
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 26, pp. 2521 - 2532
Journal Article